X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FloraStilbene (mifepristone and pterostilbene) to stimulate the immune system in advanced breast cancer patients. Preclinical data demonstrated that FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
Lead Product(s): Mifepristone,Pterostilbene
Therapeutic Area: Oncology Product Name: FloraStilbene
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
FloraStilbene (RU486 and pterostilbene) to stimulate the immune system in advanced breast cancer patients. Preclinical data demonstrated that FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
Lead Product(s): Mifepristone,Pterostilbene
Therapeutic Area: Oncology Product Name: FloraStilbene
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
JadiCell is a mesenchymal stem cell therapy having the ability to inhibit inflammasome activation and downstream chemical messengers of this inflammatory pathway, while concurrently stimulating regeneration of damaged neurons, being developed for Frontotemporal Dementia.
Lead Product(s): Mesenchymal Stem Cell
Therapeutic Area: Neurology Product Name: JadiCell
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2023
Details:
JadiCell is a mesenchymal stem cell therapy led to preserving lung function and increasing repair cell production in mice with inflammation-induced lung injury in Acute Respiratory Distress Syndrome patients.
Lead Product(s): Mesenchymal Stem Cell
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: JadiCell
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
Under the collaboration, Cure Stat Rx will manufacture first in class breast cancer immunotherapy product FloraStilbene™ for a planned 12 patient Phase I/II trial aimed at assessing immunomodulatory activity of the drug candidate in advanced breast cancer patients.
Lead Product(s): Mifepristone,Pterostilbene
Therapeutic Area: Oncology Product Name: FloraStilbene
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cure Stat Rx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 15, 2023
Details:
Company is focused on treating the “living timebomb” condition of aortic aneurysms using stem cell derived exosomes as it suppress growth of aortic aneurysms.
Lead Product(s): Stem Cell Derived Exosomes
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: VasoSome Vascular
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
JadiCell is a mesenchymal stem cell therapy led to preserving lung function and increasing “repair cell” production in mice with inflammation-induced lung injury in COPD patients.
Lead Product(s): Mesenchymal Stem Cell
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: JadiCell
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
JadiCell is a mesenchymal stem cell therapy led to preserving lung function and increasing “repair cell” production in mice with inflammation-induced lung injury in COPD patients.
Lead Product(s): Mesenchymal Stem Cell
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: JadiCell
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
FloraStilbene™ to stimulate the immune system in advanced breast cancer patients. Preclinical data demonstrated that FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
Lead Product(s): FloraStilbene
Therapeutic Area: Oncology Product Name: FloraStilbene
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
Phase III Adult Stem Cell Company Covers Ability of its COVID-19 Nutraceutical to Repair Injured Brain Cells and Stimulate Endogenous Brain Stem Cells comprising administration of green tea and/or an extract.
Lead Product(s): Green Tea Extract,Nigella Sativa Extract,Broccoli Extract
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
